Dehydroepiandrosterone sulfate

Synonyms: DHEA sulfate; Prasterone sulfate
Dehydroepiandrosterone sulfate (DHEA sulfate; Prasterone sulfate) 是一种神经甾体和肾上腺的主要分泌产物,同时具有 GABAA 受体非竞争性拮抗剂和 σ1 受体激动剂活性,可部分透过血脑屏障,通过抑制 GABAA 受体介导的氯离子内流并经 σ1 受体增强 NMDA 受体活性,发挥抗炎、抗糖皮质激素和抗抑郁作用,同时增加惊厥敏感性,还参与神经保护、神经突生长调控及儿茶酚胺分泌调节,可用于抑郁症、创伤后应激障碍 (PTSD)、阿尔茨海默病等研究,并可能是心血管疾病死亡率的生物标志物,其浓度与死亡率呈独立且负相关的关系。
产品编号: MS-F66350 纯度: 99.93% CAS No.: 651-48-9 分子式: C19H28O5S 分子量: 368.49
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
1mg
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
3-5 天
25mg
询价
3-5 天
50mg
询价
3-5 天
100mg
询价
询价
200mg
询价
询价
500mg
询价
询价

产品描述

Dehydroepiandrosterone sulfate (DHEA sulfate; Prasterone sulfate) 是一种神经甾体和肾上腺的主要分泌产物,同时具有 GABAA 受体非竞争性拮抗剂和 σ1 受体激动剂活性,可部分透过血脑屏障,通过抑制 GABAA 受体介导的氯离子内流并经 σ1 受体增强 NMDA 受体活性,发挥抗炎、抗糖皮质激素和抗抑郁作用,同时增加惊厥敏感性,还参与神经保护、神经突生长调控及儿茶酚胺分泌调节,可用于抑郁症、创伤后应激障碍 (PTSD)、阿尔茨海默病等研究,并可能是心血管疾病死亡率的生物标志物,其浓度与死亡率呈独立且负相关的关系。

生物实验数据

生物活性 Dehydroepiandrosterone sulfate (DHEA sulfate; Prasterone sulfate) is a neurosteroid and a major secretory product of the adrenal gland that acts as a non-competitive antagonist of GABAA receptors and an agonist of σ1 receptors, partially crosses the blood-brain barrier, inhibits GABAA receptor-mediated chloride ion influx and enhances NMDA receptor activity via σ1 receptors to exert anti-inflammatory, anti-glucocorticoid, and antidepressant effects while increasing seizure susceptibility, and is involved in neuroprotection, regulation of neurite outgrowth, and modulation of catecholamine secretion, making it useful for research on depression, post-traumatic stress disorder (PTSD), Alzheimer's disease, and other conditions; it may also serve as a biomarker for cardiovascular disease mortality, with its concentration showing an independent and negative correlation with mortality.
IC50 & Target

Human Endogenous Metabolite

 

Sigma 1 Receptor

 

PPARα

 

体外研究
(In Vitro)

Dehydroepiandrosterone sulfate (0.1 nM-10 μM;2-24 h) 在胚胎大鼠皮层细胞缺氧实验中显示可提高神经元存活率,且 10 μM 时效果显著。
Dehydroepiandrosterone sulfate (0.1-10 μM) 在大鼠小脑颗粒细胞氧葡萄糖剥夺实验中呈剂量依赖性保护神经元,10 μM 时几乎完全保护。
Dehydroepiandrosterone sulfate (DHEAS) (1 μM-1 mM;48 h) 在人主动脉内皮细胞炎症实验中抑制 TNF-α 诱导的 VCAM-1、IL-8 和 ICAM-1 表达,并通过激活 PPARα 抑制 NF-κB 活性。
Dehydroepiandrosterone sulfate (DHEAS) (10-7-10-5 M;96 h) 在牛嗜铬细胞增殖实验中抑制幼年细胞的 LIF 诱导增殖,增强成年细胞的 EGF 诱导增殖。

Cell Viability Assay

Cell Line: Human aortic endothelial cells (HAECs)
Concentration: 0.1 μM-1 mM
Incubation Time: 48 hours
Result: Had no significant effect on cell viability, as over 95% of cells remained viable across all concentrations tested, comparable to vehicle control.

RT-PCR

Cell Line: Human aortic endothelial cells (HAECs)
Concentration: 1 mM
Incubation Time: 48 hours (pretreatment) + 4 hours (TNF-α stimulation)
Result: Significantly reduced TNF-α-induced IL-8 and ICAM-1 mRNA expression by 5-fold and 2-fold, respectively, compared to TNF-α alone.

Western Blot Analysis

Cell Line: Human aortic endothelial cells (HAECs)
Concentration: 1-1000 μM
Incubation Time: 48 hours
Result: Increased IκB-α protein levels in a dose-dependent manner, with maximal induction at 1000 μM, correlating with NF-κB inhibition.

Cell Proliferation Assay

Cell Line: Juvenile/adult bovine chromaffin cells
Concentration: 10-7-10-5 M
Incubation Time: 96 hours
Result: Did not affect basal proliferation but inhibited LIF-induced proliferation by 30% at 10-5 M.
In adult cells, enhanced EGF-induced proliferation by 25% at 10-5 M, without effect at lower concentrations.
体内研究
(In Vivo)

Dehydroepiandrosterone sulfate (DHEAS) (1 mg/kg;静脉注射;单次) 降低白化豚鼠噪声性耳蜗损伤模型的复合动作电位阈值偏移,减少畸变产物耳声发射振幅,对耳蜗具有保护作用。
Dehydroepiandrosterone sulfate (DHEAS) (由 2 mg/kg Dehydroepiandrosterone 腹腔注射转化生成;每日 1 次;13 天) 可缩短雄性 FSL 大鼠的抑郁症模型在强迫游泳实验中的不动时间,但与电惊厥休克 (ECS) 联合使用时抵消 ECS 的抗抑郁效果。
Dehydroepiandrosterone sulfate (DHEAS) (10 mg/kg;皮下注射;每日 1 次;4 周) 增强 Laka 品系小鼠的 Pentylenetetrazol 诱导惊厥模型的惊厥敏感性,表现为降低惊厥半数有效剂量 (ED50 从 67.6 mg/kg 变为 48.6 mg/kg) 和缩短发作潜伏期,该效应可被 Progesterone (MS-E50976) 或 Dizocilpine (MS-T23155) 逆转。
Dehydroepiandrosterone sulfate 在 Pentylenetetrazol 诱发小鼠惊厥模型中慢性处理 4 周后小鼠体重显著下降。

Animal Model: Albino Guinea Pig Noise-Induced Cochlear Injury Model (250-350 g): 2 kHz pure tone (120-125 dB SPL for 10 min) induced cochlear injury
Dosage: 1 mg/kg Dehydroepiandrosterone sulfate
Administration: Intravenous injection, single dose immediately before acoustic overexposure
Result: Significantly improved cochlear function 1 week after acoustic exposure, reducing CAP threshold shifts and increasing DPOAE amplitude compared to control groups.
The protective effect was observed at 1 mg/kg but not at 0.1 mg/kg, with no significant effect immediately after exposure.
Animal Model: Flinder Sensitive Line (FSL) Rat Model of Depression (male, 200-220 g, 6-8 weeks old): forced swim test (FST) assay
Dosage: 2 mg/kg Dehydroepiandrosterone (converted to Dehydroepiandrosterone sulfate)
Administration: Intraperitoneal injection, daily for 13 days
Result: Chronic Dehydroepiandrosterone administration (converted to Dehydroepiandrosterone sulfate) alone reduced immobility time in FST, mimicking antidepressant effects.
Combined treatment with electroconvulsive shock (ECS) abolished this effect, with immobility time significantly increased compared to DHEA or ECS alone, indicating DHEAS may antagonize ECS efficacy.
Animal Model: Mouse Pentylenetetrazol-Induced Seizure Model (20-25 g): Pentylenetetrazol-induced tonic convulsions
Dosage: 10 mg/kg Dehydroepiandrosterone sulfate (dissolved in 0.1% Tween 80 saline)
Administration: Subcutaneous injection, daily for 4 weeks
Result: Chronic treatment shifted pentylenetetrazol dose-response curves leftward, reducing ED50 for convulsions and shortening latency to seizure onset, indicating enhanced seizure sensitivity.
This proconvulsant effect was prevented by co-treatment with progesterone or dizocilpine, linking it to GABAA receptor antagonism and NMDA receptor activation.
性状 固体
颜色 White to off-white

化学信息

分子量 368.49
分子式 C19H28O5S
CAS No. 651-48-9
别名 DHEA sulfate; Prasterone sulfate

储存&溶解度

体内实验配方
10% DMSO+40% PEG300+5% Tween 80+45% Saline: 3.3 mg/mL (8.96 mM), Sonication is recommended.
10% DMSO+40% PEG300+ 5% Tween 80 + 45% Saline: 10 mg/mL (27.14 mM), Solution.
10% DMSO+90% Saline: < 10 mg/mL (27.14 mM), Lower concentrations may be soluble, but exact solubility limit is unknown.
请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。
储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 100 mg/mL (271.38 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM2.7138 mL13.5689 mL27.1378 mL67.8444 mL
5 mM0.5428 mL2.7138 mL5.4276 mL13.5689 mL
10 mM0.2714 mL1.3569 mL2.7138 mL6.7844 mL
15 mM0.1809 mL0.9046 mL1.8092 mL4.5230 mL
20 mM0.1357 mL0.6784 mL1.3569 mL3.3922 mL
25 mM0.1086 mL0.5428 mL1.0855 mL2.7138 mL
30 mM0.0905 mL0.4523 mL0.9046 mL2.2615 mL
40 mM0.0678 mL0.3392 mL0.6784 mL1.6961 mL
50 mM0.0543 mL0.2714 mL0.5428 mL1.3569 mL
60 mM0.0452 mL0.2261 mL0.4523 mL1.1307 mL
80 mM0.0339 mL0.1696 mL0.3392 mL0.8481 mL
100 mM0.0271 mL0.1357 mL0.2714 mL0.6784 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础